The pharmaceutical giant presented mid-stage trial data on the pill, muvalaplin, at the American Heart Association Scientific ...

Eli Lilly LLY announced that its investigational oral, once-daily cholesterol-lowering drug muvalaplin reduced lipoprotein(a) ...

Excess cholesterol is known to form artery-clogging plaques that can lead to stroke, arterial disease, heart attack, and more, making it the focus of many heart health campaigns.

Learning that your cholesterol is higher than you'd like can be frustrating. Yet elevated cholesterol is hardly a rare condition in adults. The U.S. Centers for Disease Control and Prevention ...

Eli Lilly's muvalaplin Phase 2 trial showed significant Lp(a) reduction, meeting primary and secondary endpoints with ...

Lilly’s muvalaplin is the first oral drug to show positive Phase II findings for Lp(a) reduction, eliciting up to an 86% drop ...

Since the discovery of statins and the Scandinavian Simvastatin Survival Study (4S) results three decades ago, remarkable advances have been made in the treatment of dyslipidaemia, a major risk factor ...

Managing diabetes and high cholesterol often requires lifestyle changes, such as eating healthier, exercising, and sometimes ...

Doctors say they have not seen anything like this since the emergence of statins to lower cholesterol. But do we know enough ...

Dr. B. Keith Ellis, MD, director of cardiovascular services and the director of the Chest Pain Center at Houston Methodist ...

Eating plant-based foods that are rich in fiber and healthy fats through what’s long been known as the portfolio diet is one ...